Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation & Amortization (IS): 2024-2025

Historic Depreciation & Amortization (IS) for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Sep 2025 value amounting to $100,000.

  • Amylyx Pharmaceuticals' Depreciation & Amortization (IS) fell 50.00% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $600,000, marking a year-over-year change of. This contributed to the annual value of $900,000 for FY2024, which is 18.18% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Depreciation & Amortization (IS) stood at $100,000 for Q3 2025, which was down 0.00% from $100,000 recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Depreciation & Amortization (IS) high stood at $300,000 for Q1 2024, and its period low was $100,000 during Q2 2025.
  • For the 2-year period, Amylyx Pharmaceuticals' Depreciation & Amortization (IS) averaged around $185,714, with its median value being $200,000 (2025).
  • Data for Amylyx Pharmaceuticals' Depreciation & Amortization (IS) shows a maximum YoY plummeted of 50.00% (in 2025) over the last 5 years.
  • Over the past 2 years, Amylyx Pharmaceuticals' Depreciation & Amortization (IS) (Quarterly) stood at $200,000 in 2024, then slumped by 50.00% to $100,000 in 2025.
  • Its Depreciation & Amortization (IS) was $100,000 in Q3 2025, compared to $100,000 in Q2 2025 and $200,000 in Q1 2025.